bevacizumab,trifluridine tipiracil,taiho pharma
roche,otsuka,taiho pharma
[]
#gi23
oral abstracts: crc abstracts 4 (sunlight) and 5 (cfdna in st i-iii crc)
discussant: abstract 4: sunlight primary ep: os for ftd/tpi + bev vs ftd/tpi in pts with refractory mcrc practice changing! 
Oncologist | Focus on #NETs | Mom | she/her 
Division Chief, GI Oncology @YaleCancer | Consultant Editor @JCO_ASCO |
Tweets mine | ASCO FCOI: https://t.co/UuqIAQ5Civ